Eric Wang, Ph.D.

Assistant Professor

Investigating mechanisms of drug resistance in hematological malignancies with the main goal to develop new therapeutic strategies and providing a blueprint for clinically relevant biomarkers.

Acute myeloid leukemia (AML) is an aggressive hematological malignancy that accounts for majority of acute leukemia cases in adults. Despite recent therapeutic advances, AML is still marked by a dismal prognosis. Our laboratory is interested in understanding mechanisms that govern therapy resistance in hematological malignancies by using CRISPR/Cas9 technology and genetically engineered mouse models.

         Download CV          

Visit Personal Lab Site